Jeff E. Knight Crinetics Pharmaceuticals, Inc. (CRNX) insider trading activity

Jeff E. Knight is Chief Operating Officer of Crinetics Pharmaceuticals, Inc.. Currently has a direct ownership of 51,653 shares of CRNX, which is worth approximately $2.79 Million. The most recent transaction as insider was on Nov 22, 2024, when has been sold 501 shares (Common Stock) at a price of $56.52 per share, resulting in proceeds of $28,316. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 51.7K

0% 3M change

50.15% 12M change

Total Value Held $2.79 Million

Jeff E. Knight Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 22 2024	SELL Open market or private sale	$28,316 $56.52 p/Share	501 Reduced 0.96%	51,653 Common Stock
Jul 15 2024	SELL Open market or private sale	$1,485,000 $55.0 p/Share	27,000 Reduced 34.33%	51,653 Common Stock
Jul 15 2024	BUY Exercise of conversion of derivative security	$553,008 $21.21 p/Share	26,073 Added 24.9%	78,653 Common Stock
Jun 26 2024	SELL Open market or private sale	$42,427 $44.38 p/Share	956 Reduced 1.79%	52,580 Common Stock
Mar 22 2024	SELL Open market or private sale	$1,450,006 $44.81 p/Share	32,359 Reduced 38.1%	52,580 Common Stock
Mar 22 2024	BUY Exercise of conversion of derivative security	$719,400 $23.98 p/Share	30,000 Added 26.1%	84,939 Common Stock
Mar 18 2024	SELL Payment of exercise price or tax liability	$163,353 $38.14 p/Share	4,283 Reduced 7.23%	54,939 Common Stock
Mar 04 2024	BUY Grant, award, or other acquisition	-	23,000 Added 27.97%	59,222 Common Stock
Mar 16 2023	SELL Payment of exercise price or tax liability	$10,049 $17.12 p/Share	587 Reduced 1.68%	34,400 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	29,500 Added 45.75%	34,987 Common Stock
Jul 26 2022	SELL Open market or private sale	$23,846 $20.7 p/Share	1,152 Reduced 18.88%	4,950 Common Stock
May 20 2022	BUY Other acquisition or disposition	$20,091 $17.44 p/Share	1,152 Added 15.88%	6,102 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	-	4,950 Added 50.0%	4,950 Common Stock

JEK

Jeff E. Knight

Chief Operating Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRNX shares.

Notify only if

Value

Insider Trading

Get notified when an Crinetics Pharmaceuticals, Inc. insider buys or sells CRNX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Crinetics Pharmaceuticals, Inc.

Track Activities on CRNX

Account